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Abstract 
In Gene therapy Nucleic acids can be inserted into human cells to provide enhancement or reduction of protein 
expression for the prevention, treatment or elimination of  the problem. For this to happen foreign  gene should 
be inserted in to the cells using different mechanisms. The  commonly used ways of gene delivery in to 
eukaryotic cells are of viral and non viral delivery systems. The non viral delivery are of different types of which 
the liposome mediated tranfection  is the most widely used. Liposome mediated  transfect ion represent approved 
non-toxic biocompatible nanoparticles for the application of medicine. Excellent biocompatibility, low 
immunogenicity, delivery of large piece of nucleic acid and simplicity of handling are the major advantages one 
has to see in liposome transfection. But the presence of positive charge on liposomes vectors which may favour 
nonspecific interaction with negatively charged serum protein, enzymes and causing in to decreased cell 
adhesion, hemolysis and low transfection are among the disadvantages. In this short review different types of 
liposomes and their reagents are  highlighted. Generally the use liposome in the area of biomedicine (not only for 
gene delivery) gives a paramount relief specially in this era of drug resistance, vaccine failure, threatening 
emerging and re-emerging pandemics in the globe.  
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1. INTRODUCTION TO GENE THERAPY 
Nucleic acids can be used as a drug for diseases of known genetic basis by correcting missing genes, replacing 
defective genes, or down-regulating aberrant gene expressions with efficient delivery. There are mainly two 
classes of vehicles for gene delivery: (i) viral and (ii) non-viral vectors2.  In Gene therapy genetic material is 
inserted into human cells to provide enhancement or reduction of protein expression for the prevention, 
treatment or elimination of disease. However, clinical implementation has been difficult4.  
Gene therapy starts with the identification of mutant gene causing the disease, cloning the identical 
healthy gene (therapeutic gene or transgene) which suppress or repair the problem. After producing the 
therapeutic gene it is loaded in a vector vehicle (the most critical step) so that to deliver the therapeutic gene to 
the patient target cell. Then the genetic material is delivered to the nucleus and integrated into DNA and corrects 
the defective or mutated gene(figure1)5. Gene delivery by using Lipid is most successful in both dividing and 
non-dividing cells where DNA entrance into the nucleus but entry to later cells happens at a low frequency6. 
 
 
Figure 1: schematic illustration of gene therapy5 
Adverse immunogenic reactions, insertional mutagenesis, and toxicity limits the application as well as 
the use of clinical trials in viral vectors where as Non-viral  vector which uses positively charged polymers, 
peptides, or lipids forms self-assemblies with high DNA carrying capacity, ease of preparation, and lower 
immunogenicity and cytotoxicity but less efficient  as compared to viral vectors2. 
 
2. PRINCIPLE OF LIPOSOME MEDIATED GENE DELIVERY 
Liposomes are among non-viral vectors formed from hydrophilic head group and hydrophobic tails and then 
self-assemblein a dissolved lipid molecules. The energetically favorable interacting lipids  forms a vesicular fluid 
entities with versatile supramolecular assemblies which can be used for gene and drug delivery as a liposomes7. 
Liposomal drug delivery systems are industrial technologies which represent approved non-toxic biocompatible 
nanoparticles for the application of medicine. They are used for the entrapment of lipophilic and hydrophilic 
agents likedrugs into the liposomes to bypass the frequent toxicity or inappropriate drug formulation.The 
formulation of the Liposomeof desired composition, morphology, size distribution and surface modification 
depends on cells that is going to be transfected8.  
The non-viral vector gene delivery is influenced by the quantity and quality of deoxyribonucleic acid 
(DNA), ratio of DNA to material, serum, antibiotics, solvent for DNA and material, incubation time, and mixing 
order. Lipofectamine™ 2000 (Lipo2000) is one of the highly efficient and most widely used commercial 
cationic lipids for in vitro gene transfer. The unbinding of DNA from CLs is not completely understood, but 
thought to result from charge neutralization by cellular anionic lipids that changes structure of lipoplexes  
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radically upon interaction with cellular lipids taken up by a cell via the plasma membrane, undergo endosomal 
escape in order to avoid lysosomal degradation and active transport to the nucleus for subsequent transcription 
(figure 
1)9.
 
Figure 2. Liposome-mediated transfection and endocytosis10. 
To avoid these mentioned disadvantages heterocyclic ring  with positivechargesare used11. But all this 
exhaustive and extensive efforts yield very limited improvements clinically12 . 
Due to variability of  morphologies, compositions, abilities to envelope and protect many types of 
therapeutic biomolecule as well as lack of immunogenic response, low cost, and their differential release 
characteristicsthe applications  of lipid vesicles  is also variable7. 
The synthetic liposomes spheres withone or more bilayered membrane surrounding an aqueous core to 
encapsulate small molecules are used (Figure 3A,3B). Self-assembly of liposome happen due to the  interaction 
of  lipids with DNAand influenced by preparation procedure, mixing ratio, DNA concentration, and size of the 
cationic liposomes and ionic strength of the buffer11.The transfection efficiency improvement and cytotoxicity 
reduction forced synthetic modifications of the liposome by using positivecharges ofhead group. This is done by 
introducing   heterocyclic ring (imidazolium pyridinium) and protonated polyamine groups into cationic 
liposomes to decrease the positive charge of the cationic head as well as modification with the linker 
functionalization group which improve the properties of liposomes.Ether linked liposome arenot biodegradedand 
have higher toxicity despite their good transfection efficiency13,  but ester or amide linkers are more 
biodegradable and less toxic in cultured cells and are alsodegradable in the circulatory system14. Besides, 
polyethylene glycol (PEG) and/or other molecules such as ligands and peptides linked cationic liposomes 
(Figure 3C,3D) has been  shown as a great improvement leading to small particle sizes, controlled structures, 
regular morphology, and good stability15. A number of structures appeared during polynucleotides compaction 
into liposomal assemblies. A specific structure of the assembly happen with energetically favorable 
conformation.(figure3)16. 
 
 
 
 
Figure 3: Schematic representation of the 
structure of liposomes(Adapted from16). 
A: One bilayered membrane liposome 
B: Two bilayered membrane liposome 
C, D: linked cationic liposomes 
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3. TYPES OF LIPOSOME  
3.1. Cationic lipids 
The most commonly  used commercial reagents for cationic lipid transfection are N-[1-(2,3 dioleyloxy)propyl]-
N,N,N-tri methyl ammonium chloride (DOTMA),[1,2-bis(oleoyloxy)-3-(tri-methyl ammonio) propane] 
(DOTAP), 3β[N-(N′, N′-dimethylaminoethane)-carbamoyl] cholesterol (DC-Chol)], and 
dioctadecylamidoglycylspermine (DOGS). Dioleoylphosphatidylethanolamine (DOPE is  a neutral lipid used in 
together with cationic lipids infavour  of its membrane destabilizing effects in endolysosomal escape16. 
Cations together withpolymers, lipids, and non-degradable nanoparticles theyare used asnon-viral gene 
deliver vectors.Hydrocarbon of both symmetric and asymmetric chains are used in a lipid mixture, but 
asymmetric lipid with both shorter saturated and long unsaturated carbon chains have a relatively high 
transfection efficiencies compared to mixed symmetric formulations of cationic lipids. Hydrophobic tails and 
ionizable head groups of multivalent cationic lipids (DOSPA and DOGS)serve as a buffer during protons influx 
into a maturing endosome/endolysosome.This is the reason why multivalent cationic lipids have higher 
transfection efficiencies compared to their monovalent counterparts17. 
3.1.1. Monovalent Cationic Lipids 
A. DOTMA 
N-[1-(2, 3-dioleyloxy) propyl]-N, N, N-trimethylammonium chloride, or DOTMA, is the first  to be synthesized 
and commercially available cationic lipids in gene delivery. The structure consists of 2 unsaturated oleoyl chains 
(C18: ∆9), connected by an ether bond to three-carbon skeleton of glycerol and quaternary amine as the cationic 
head group. DOTMA interacts spontaneously with DNA to form lipid-DNA complexes.This lipid facilitates 
fusion of the complex with the plasma membrane of tissue culture cells which leads to uptake and expression of 
the DNA. It is a simple transfection methodwith high reproducible capacity applied for both transient and stable 
expression of DNA at about100-fold more effective than either the calcium phosphate or the DEAE-dextran 
transfection18.Transfection efficiencies was increased by using Combination of DOTMAwith DOPE inan equal 
ratio which adds functional groups to the main lipids. Manipulation in the head group, linker, linkage bonds, and 
hydrocarbon chains  of DOTMAhave indicated reduction in toxicity and increased transfection efficiencies19. 
B. DOTAP 
Leventis and Silvius in 1990 synthesized [1, 2-bis (oleoyloxy)-3-(trimethylammonio) propane], or DOTAP for 
the first time. The molecular sturucture consists of a four amine head group connected to glycerol backbone with 
two oleoyl chain linked by ester bond. This monovalent lipids also showed almost no cytotoxic effect on cell 
monolayers with good lipoplex sensitivity at 25%–35% cell confluency19.The use of naked DOTAP is inefficient 
due to its protonation at pH 7.4.This costsmore energyto separate the DNA from the lipoplex for efficient 
transfection. Thus, DOTAP should  be combined with a helper lipid like  most cationic lipid formulations7.  
In both DOTMA and DOTAP resistance to serum interaction is observed even though the way how the 
interaction happens is unknown but it ishypothesized that binding to cell membranes, structural complex 
maturation inhibition, binding to cationic charges and the disparity of endocytosis pathways are the 
speculation.20. 
C. DC-Chol 
Gao and Huang in 1991 synthesized for the first time [3β [N-(N', N’-dimethylaminoethanecarbamoyl] 
cholesterol, or DC-Chol by attachingcholesterol moiety using an ester bond to the main structure. DC-Chol 
waschosen for its biocompatibility, stability to lipid membranes and have a four timesreduction in cytotoxicity 
compared to Lipofectin in some cell lines21. DC-Chol, in equal  lipid ratio with DOPE, contains a tertiary amine 
where  50% of the liposome surface is  charged at pH 7.4 as opposed to DOTMA and DOTAPwhich are  fully 
charged22.  This  charge reduction helps in DNA dissociation, successful transfection and  higher transgene 
expression23. 
3.1.2. Polyvalent Cationic Lipids 
A. DOSPA 
DOSPA is structurallyanalogues to DOTMA but the spermine group here isconnected to hydrophobic chainsby 
peptide bond. The commercial available transfection reagent Lipofectamine is formed of this cationic lipid and 
DOPE at a 3: 1 ratio.Efficient packing of DNA is achieved by the addition of the spermine ammonium functional 
group7. 
B. DOGS 
Structurally Di-octadecyl-amido-glycyl-spermine, or DOGS is similar with DOSPAby the presence of 
polyvalent spermine head group and alkyl chains of the two 18-carbon. Clear differences are observed on the 
chains of DOGS which are saturated and linked to head group by a peptide bond on top lacks a quaternary amine 
group. This kit  is commercially available as Transfectam to be used in many cell lines with good efficiency up 
to  10-fold better than  calcium phosphate transfections with no noticeable cytotoxicity24. 
Additional to efficient condensation of DNA, the delivered DNA from degradation wasprotectedby 
head group of DOGS buffering ability of the endosomal compartment. DOGS do have  buffering capacityat pH 
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values below 4.6 whenall of the amino groups in the spermine are protonated, but  at pH = 8 only two are ionized, 
and  promotes arrangement into a lamellar structure25.  
 
3.2.Modified Liposome 
3.2.1. Poly (ethylene) Glycol 
PEG is a linear polyether diolthat modifies physical adsorption onto the liposomal surface and its covalent 
attachment onto premade liposomes. This results in less toxic, biocompatible, ready excretion and ease of 
application. The presence of PEG on the surface of the liposomal carrier has been shown to extend blood-
circulation time while reducing mononuclear phagocyte system uptake (stealth liposomes) of the intended gene 
to be delivered26. 
The PEG-coating has sterically stabilizes the liposomal membrane against interactions with 
destabilizing and opsonic factors in vivo. As a result it shows longer circulation times and reduced uptake by the 
Macrophages, relative to conventional liposomes. Although the exact mechanism behind the Macrophages 
avoidance phenomenon  assumed  that by the formation of a highly hydrated shield of polymer molecules around 
the liposome which sterically inhibits both electrostatic and hydrophobic interactions of serum components with 
the liposomal bilayer1.  
 
3.3. Neutral Lipids 
A. DOPE and DOPC 
Inclusion of “helper” lipids in the cationic liposomes improves lipoplex efficiency by increasing lipid self-
assembly (micellar, lamellar, hexagonal, vesicular, etc.), the level of hydration, and DNA secondary and tertiary 
structure. 1, 2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), is used as a helper lipid for in vitro 
transfection with bettermatching of charge density to the DNAequal ratio of DOTAP/DOPE is neutralized and 
complexed with the negatively charged DNA. Due to salt bridges of the positively charged head groups of the 
lipids and the phosphate groups of DOPE. This would force the stabilization of primary amine group of DOPE to 
itself by allowing more close interactions with the negatively charged phosphate of the DNA. This 
reducespositively charged lipid head group, thus lowering the energy required for binding DNA23. 
DOPC  is a much better helper lipid for in vivo transfection27. There are also Galactosylated cholesterol 
derivatives with decreased cytotoxicity and improved transfection efficiencies in Hep G2 cell lines. This is 
probably due to thehigh affinity of cellular receptors for galactosylated ligands for specific uptake28. 
 
3.4. Anionic Liposome 
The most commonly used anionic lipids are phospholipids which are found in cellular membranes naturally like 
phosphatidic acid, phosphatidylglycerol, and phosphatidylserine. This lipids also have fatty acid chains in the 
hydrophobic region. Even though they are not efficient gene delivery agents because of   negatively charged 
head group that prevents efficient DNA compaction as a result of electrostatic repulsiveforces the phosphate 
backbones of DNA they are selected because of resolving cationic lipids draw backs. Among which serum 
inactivation, unstability upon storage, and in vitro and in vivo cytotoxicity aresolved by these group of lipids. 
Here DNA-containing liposomes are formed by divalent cations bydenying the mutual electrostatic repulsion to 
form lipoplex assembly. The incorporated fatty acids are responsible for the fluidic characteristics in terms of 
phase behavior and elasticity29. 
 
3.5. pH sensitive liposomes 
These liposomes are destabilized by the endocytotic pathway because of the effectof acidic conditions and pH-
sensitive lipid components. This enables thecontent to be delivered into the intracellular bio-environment or its 
fusion with the endosomal membrane. Their therapeutic efficacy allow them to be used as biomaterial with 
commercial utility especially in cancer treatment. Another way how this liposome, are used is by targeting 
ligands (antibodies) which can be anchored on the surface ofpH-sensitive liposomes so that they targets specific 
cell surface receptors/antigen present on tumor cells30.  
 
3.6. Fusogenic liposome  
The discovery of Okada et al 1985 describes conventional liposome as well as cell membranes can efficiently be 
fused by Sendai virus using virus envelope protein to form fusogenic liposomes. Commercially it can be 
prepared when unilamellar liposomes are fused with the purified Sendai virus. Fusogenic liposomes delivered 
their contents into the cytoplasm via an endocytosis-independent pathway as compared to conventional 
liposomes which are taken up by endocytosis. The main advantage of Fusogenic liposomes is to avoid the 
immediate split   of the gene by lysosomal enzymes, thus; providing a vehicle for the delivery of the contents 
into the cytoplasm (figure 4). These liposomes can also be used to deliver encapsulated contents into the 
cytoplasm of a wide variety of mammalian cells3. 
Advances in Life Science and Technology                                                                                                 www.iiste.org 
ISSN 2224-7181 (Paper) ISSN 2225-062X (Online) 
Vol.51, 2016 
 
5 
 
 
3.7. Immunoliposome 
This was first described as antibody-targeted liposomes (immunoliposomes) by Torchilin et al in early 
1970eswhere it specifically bind to the antigen that is expressed on the target cells. After wards coupling 
techniques were used for conjugating antibodies or their fragments to liposomes (Figure5). Up on in vitro 
experiments immunoliposomes are highly specific in binding to target cells.  Sterically stabilized PEG–
liposomesare used for coupling antibodies by different methods. The coupling is   done by attaching the ligand 
directly to the liposome bilayer and attaching the ligand to the terminal end of PEG. The clearance rate of PEG–
immunoliposomes is dependent on the antibody density at the liposome surface. At low antibody density (<≈50 
µg mAb/µmol PL), the PEG–immunoliposomes are cleared at rates slightly more rapidly than antibody-free 
PEG–liposomes but very rapid at higher antibody density (>100 µg mAb/µmol PL)1. 
  
 
4. CONCLUSIONS  
Nucleic acids is a drug for diseases in that it helps correcting genetic problems and protects from infectious 
diseases.  For this to happen an efficient delivery system should be chosen. Known delivery system are of the 
viral and the non-viral ones with both having their own advantage and disadvantages. But the non-viral delivery 
reagents are better than the viral delivery methods in that the disadvantages are less as compared to the viral or 
modification may change the behavior of the agent. Among the non-viral vectors liposomes having various array 
of morphologies, compositions, capabilities to envelope and shield many types of therapeutic biomolecule are 
the best transfection reagents. So the use of these liposome in the area of biomedicine gives a paramount relief 
specially in this era of drug resistance, vaccine failure, threatening emerging and re-emerging pandemics in the 
globe. 
 
Figure4:Fusogenic liposomes as 
efficient delivery vehicles into the 
cytoplasm3 
 
Figure5: Currently used PEG–
immunoliposomes types1 
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